| Literature DB >> 34363728 |
Aditya K Gupta1,2, Mesbah Talukder2.
Abstract
The use of cannabis for skin diseases and hair regrowth is at the preliminary stage. LEGALIZATION: Many countries have approved cannabis for medical use; however, four countries Canada, Uruguay, South Africa, and Georgia have legalized it for both medical and recreational purposes. THE ENDOCANNABINOID SYSTEM: The endocannabinoid system may maintain skin homeostasis; two notable endocannabinoids include 2-Arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (AEA). ROUTES OF ADMINISTRATION AND PHARMACOKINETICS: Topical cannabinoids can avoid the first-pass metabolism and reduce respiratory side effects; however, the high hydrophobicity of cannabinoids may hinder percutaneous absorption. SKIN DISORDERS AND HAIR GROWTH: Human clinical studies suggest that cannabinoids may be used in eczema, acne, pruritus, and systemic sclerosis treatment. Cannabidiol (CBD) may enhance hair growth via multiple mechanisms. SAFETY: Topical cannabis may cause mild side effects such as pruritus, burning, erythema, and stinging; they are relatively safer than inhalation and oral cannabis. Cannabis use may be associated with allergic symptoms and reduced immune response to live vaccination. CANNABINOIDS IN PRACTICE: Despite growing interest, dermatologists should be cautious prescribing cannabinoids due to insufficient clinical data on both efficacy and safety.Entities:
Keywords: cannabidiol; cannabinoids; endocannabinoid system; hair growth; skin diseases
Year: 2021 PMID: 34363728 DOI: 10.1111/jocd.14352
Source DB: PubMed Journal: J Cosmet Dermatol ISSN: 1473-2130 Impact factor: 2.696